期刊文献+

尼可地尔对冠心病合并2型糖尿病不完全血运重建术后的疗效观察 被引量:8

The efficacy of Nicorandil in Patients with Multivessel Coronary Artery Disease Complicated with Type 2 Diabetes Undergoing Incomplete Revascularization
原文传递
导出
摘要 目的:比较尼可地尔与单硝酸异山梨酯对冠心病合并2型糖尿病患者不完全血运重建术后的疗效。方法:入选112例经皮冠状动脉介入治疗(PCI)部分血运重建的冠心病合并2型糖尿病患者。随机分为2组:尼可地尔组(5 mg,3次/d,口服)60例,单硝酸异山梨酯组(50 mg,1次/d,口服)52例,两组患者均给予常规冠心病及糖尿病药物治疗。术后4周末行运动负荷试验,观察总运动时间,从开始运动到出现ST段压低1.0 mv和出现心绞痛的时间(s),以及最大ST段压低幅度,同时记录每周心绞痛发作次数及硝酸甘油用量。结果:4周后两组患者同服药前比较,从开始运动到出现ST段压低1.0 mv的时间延长,总运动时间延长,从开始运动到出现心绞痛的时间延长,最大ST段压低幅度降低(P<0.01),但尼可地尔组与单硝酸异山梨酯组比较无明显统计学差异(P>0.05);尼可地尔组每周心绞痛发作次数及硝酸甘油用量明显少于单硝酸异山梨酯组(P<0.05)。结论:尼可地尔可增加冠心病合并糖尿病患者行不完全血运重建术后患者运动耐量,在减少心绞痛方面作用优于单硝酸异山梨酯。 Objective:To assess the efficacy between Nicorandil and isosorbide mononitrate in patients with multivessel coronary artery disease complicated with type 2 Diabetes undergoing incomplete revascularization by percutaneous coronary intervention(PCI).Methods:Patients(n=112) with multivessel coronary artery disease complicated with type 2 Diabetes suffered incomplete revascularization by PCI were randomly divided into 2 groups:Nicorandil group(N=60) and isosorbide mononitrate group(N=52).Exercise tolerance test,number of weekly angina attacks,nitroglycerin consumption were evaluated.Results:Both groups improve the total exercise time and the time to 1 mv ST-segment depression in an exercise tolerance test,there was no significant difference between the two groups,however,Nicorandil significantly decreased the number of angina attacks and nitroglycerin consumption.Conclusions:Nicorandil may have better antianginal effect than isosorbide mononitrate as treatment for patients after incomplete revascularization by PCI with type 2 Diabetes.
出处 《现代生物医学进展》 CAS 2014年第12期2299-2302,共4页 Progress in Modern Biomedicine
关键词 尼可地尔 冠心病 2型糖尿病 不完全血运重建 Nicorandil Coronary artery disease Type 2 Diabetes Incomplete revascularization
  • 相关文献

参考文献20

  • 1Wang Y, Yu Q, Fan D, et al. Coronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies [J]. Ex- pert Rev Cardiovasc Ther, 2012, 10(8): 1051-1060.
  • 2G?ssl M, Faxon DP, Bell MR, et al. Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease [J]. Circ Cardiovasc In- terv, 2012, 5(4): 597-604.
  • 3Horinaka S. Use of nicorandil in cardiovascular disease and its optimization[J]. Drags, 2011, 71(9): 1105-1119.
  • 4Hahalis G, Dangas G, Davlouros P, et al. Revascularization strategies for stable multivessel and unprotected left main coronary artery disease: from BARI to SYNTAX [J]. IntJ Cardiol, 2011, 153(2): 126-34.
  • 5Hasdai D, Lerman A, Grill DE, Rihal CS, Holmes DR.Medical therapy aider successful percutaneous coronary revascularization [J]. Ann intem Med, 1999, 130: 108-115.
  • 6Thadani U, Rodgers T. Side effects of using nitrates to treat angina[J]. Expert Opin Drug Saf, 2006,5(5): 667-674.
  • 7Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology [J]. European heart Journal, 2006, 27:1341-1381.
  • 8无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2060
  • 9Falase B, Easaw J, Youhana A. The role of nicorandil in the treatment of myocardial ischaemia [J]. Expert Opin Pharmacother, 2001, 2(5): 845-856.
  • 10Vasodilatory effect ofnicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels [J]. Journal of Cardiovascular Pharmacology, 1995, 26:541-547.

二级参考文献75

  • 1The IONA Study Group.Effect of nicorandil on coronary events in patients with stable angina:the Impact of Nicorandil in Angina(IONA) randomised trial[J].Lancet,2002,359(9314):1269-1275.
  • 2Matsuo H,Watanabe S,Segawa T,et al.Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil[J].Eur Heart J,2003,24(14):1296-1303.
  • 3Ishida H,Higashijima N,Hirota Y,et al.Nicorandil attenuates the mitochondrial Ca2+ overload with accompanying depolarization of the mitochondrial membrane in the heart[J].Naunyn Schmiedebergs Arch Pharmacol,2004,369(2):192-197.
  • 4Nameki M,Ishibashi I,Miyazaki Y,et al.Comparison between nicorandil and magnesium as an adjunct cardioprotecti veagent to percutaneous coronary intervention in acute anterior myocardial infarction[J].Circ J,2004,68(3):192-197.
  • 5IONA Study Group.Determinants of coronary events in patients with stable angina:results from the impact of nicorandil in angina study[J].Am Heart J,2005,150(4):689.
  • 6Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology, 2000,94 ( 1 ) :31-35.
  • 7Ryden L, Standl E, Bartnic M, et al. Guideline on diabetes, prediabetes and cardiovascular disease:executive summary. The Task Force on Diabetes and Cardiovascular Disease of European Society of Cardiology (ESC) and of the Euopean Association for the Study of Diabetes(EASD). Eur Heart J,2007,28( 1 ) :88-136.
  • 8Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology.J Am Coll Cardiol,1999,34(3) :912-948.
  • 9Campeau L. Letter: Grading of angina pectoris. Circulation 1976 :54(3) :522-523.
  • 10O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol, 2000,36(1) :326-340.

共引文献2092

同被引文献59

引证文献8

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部